Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-102 in GPC3-Expressing Solid Tumors
NCT04405778Phase 1Terminated
- Sponsor
- Takeda
- Start
- Jul 2020
- Primary completion
- May 2025
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label trial of TAK-102 in solid tumor (3 cohorts), sponsored by Takeda. Primary endpoints: Dose-Limiting Toxicities at 28 days, Treatment-emergent Adverse Events at 3 years and 1 more. Started Jul 2020; status: terminated.
02
Drugs
TAK-102
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04405778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04405778.